Titlebook: Cellular Cancer Markers; Carleton T. Garrett,Stewart Sell Book 1995 Springer Science+Business Media New York 1995 antibody.cancer.cell.leu

Custodian

自然環(huán)境

Genetic Changes in Breast Cancer,veness and metastasis (Lipmman and Dickson, 1988). Several epigenetic factors influence the development of breast cancer. These seem to be related to the timing and degree of exposure to hormones and growth factors, such as age of menarche, menopause, first pregnancy, and breast feeding (Lipmman and

蜿蜒而流

Genetic Alterations in Lung Cancer,ng cancer incidence in males is second only to prostate cancer, and in females, it is second only to breast cancer (Miller et al., 1992a). Unfortunately, despite recent advances in oncologic therapy, survival from lung cancer remains poor, as indicated by an overall 5-yr relative survival rate of 13

SSRIS

一再困擾

,Phenotypic Expression of Hodgkin’s Disease,to indicate markers that are known to be associated with T-lymphocytes. This by no means suggests that these markers are exclusive to T lymphocytes or diagnostic for T-cell lymphoma. The same principle applies to the terms “B-cell markers” and “histiocyte markers.” We use the word “markers” to defin

先鋒派

Melanoma Markers,ituents are useful in studying the pathobiology of melanocytic neoplasms, as diagnostic markers in histopathology, and as biochemical tools for therapy. The characterization of numerous melanoma-associated antigens and cytogenetic abnormalities present in benign, atypical, and malignant melanocytes

Generator

Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma,nal expansions of lymphoid cells. For decades, the production of a single type of light chain by B-cell neoplasms has been exploited to indicate the monoclonality of a lesion; the clonal immunoglobulin produced by one tumor is unique, and is not exactly the same as that produced by any other B-cell

決定性

P-Glycoproteins in Tumors,in’s disease, large-cell lymphoma, acute lymphocytic leukemia, and testicular cancer to the point that these entities are now considered to be “curable.” In addition, with the development of combination chemotherapy, other malignancies, such as ovarian cancer, small-cell lung cancer, and advanced br

茁壯成長

Genetically Engineered Antitumor Monoclonal Antibodies,unleashed a vast array of possibilities for the generation of monoclonal antibodies (MAbs) for use in diagnosis and therapy of cancer and other diseases, several limitations inherent to MAbs exist. For example, MAbs of the desired specificity may be difficult or even impossible to generate using cur

Definitive